Evidence map›Paper›PMID 33274196›Full record

ArticleBioMed research international2020

Prognostic Significance of COVID-19 Receptor ACE2 and Recommendation for Antihypertensive Drug in Renal Cell Carcinoma.

Kihun Kim, Yeji Ko, Dai Sik Ko, Yun Hak Kim

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Kihun KimDepartment of Occupational and Environmental Medicine, Kosin University Gospel Hospital, Republic of Korea.
Yeji KoDepartment of Statistics, University of Michigan, Michigan, USA.
Dai Sik KoDivision of Vascular Surgery, Department of Surgery, Gachon University Gil Medical Center, Republic of Korea.ORCID https://orcid.org/0000-0002-8858-4025
Yun Hak KimDepartment of Biomedical Informatics, School of Medicine, Pusan National University, Republic of Korea.ORCID https://orcid.org/0000-0002-9796-8266
Gachon University Gil Medical Center · KRKosin University Gospel Hospital · KRPusan National University · KRUniversity of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOwing to its worldwide spread, the coronavirus disease (COVID-19) epidemic was declared a pandemic by the World Health Organization on March 11, 2020. Angiotensin-converting enzyme 2 (ACE2) is the outer surface protein of the cell membrane that is abundantly distributed in the heart, lungs, and kidneys and plays an important role in molecular docking of the severe acute respiratory syndrome coronavirus 2. In this study, we aimed to analyze the difference in the survival rate according to ACE2 expressions in pan-cancer. MATERIALS AND

methodsWe downloaded clinical and genomic data from The Cancer Genome Atlas. We used Kaplan-Meier with a log-rank test, and the Cox proportional hazards regression to analyze prognostic significance.

resultsIn the Kaplan-Meier curve, clear cell renal cell carcinoma (ccRCC), uveal melanoma, and prostate adenocarcinoma showed statistical significance. In the Cox regression, thyroid carcinoma and glioblastoma multiforme and ccRCC showed significant results. Only ccRCC had statistical significance, and high ACE2 expression is related to good prognosis. It is known that the ACE inhibitor, a primary antihypertensive agent, increases ACE2 expression.

conclusionBased on these results, we believe that the ACE inhibitor will be important to increase the lifespan of ccRCC patients. This study is the first research to offer a recommendation on the use of anti-hypertensive drugs to ccRCC patients.

Indexed as

Carcinoma, Renal CellCOVID-19COVID-19 Drug TreatmentKidney NeoplasmsAngiotensin-Converting Enzyme 2Antihypertensive AgentsDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansMaleNeoplasm ProteinsSurvival RateACE2 protein, humanAngiotensin-Converting Enzyme 2Antihypertensive AgentsNeoplasm Proteins

Identifiers

PMID33274196
PMCPMC7695994
OpenAlexW3107153875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.